Personalized medicine has long promised a future where every patient gets treatment tailored to their unique needs. But the reality has been a slow, manual, and outdated compounding process—especially risky for children, cancer patients, and those with chronic or rare conditions. Finnish healthtech startup CurifyLabs is changing that narrative with a bold new approach to modern drug preparation.
The Helsinki-based company just closed a €6.7 million funding round to bring automation to pharmaceutical compounding. Led by Finnish private investment platform Springvest and supported by a €1 million deep tech loan from Business Finland, the funding will help scale operations, grow the customer base, and commercialize CurifyLabs’ intelligent compounding system across Europe.
Despite rising demand, just 1% of medications today are personalized through compounding. Many patients struggle with drug allergies or unsuitable forms, while nearly half of all medications are unavailable in child-friendly doses. Manual compounding takes time, requires highly skilled pharmacists, and often leads to inconsistent results. CurifyLabs steps in with a tech-forward solution designed to fix these gaps.
At the heart of its innovation is the Compounding System Solution (CSS)—a platform combining software, pharmaceutical-grade excipients, and a desktop-sized “Pharma Printer” that automatically dispenses precise dosages. The system is paired with a cloud-based formulation library, offering pharmacists access to verified recipes for liquids, ointments, suppositories, and tablets. Built-in quality control ensures consistency, while the system speeds up production by 4x compared to traditional methods.
Unlike conventional 3D printing methods that require lengthy prep and clean-up, CurifyLabs’ system is built for real-world pharmacy environments. It makes daily compounding faster, safer, and more scalable—especially critical for pediatric, geriatric, and immunocompromised patients.
The startup’s roots lie in academia and hands-on experience. Co-founded by Niklas Sandler, a pharmaceutical researcher inspired by his pharmacist mother, and entrepreneur Charlotta Topelius, CurifyLabs blends deep scientific knowledge with commercial drive. Together, they’re tackling one of the most overlooked—but essential—parts of patient care.
Their system has already been validated in a peer-reviewed Europe-wide study, involving 30 healthcare facilities and confirming the platform’s accuracy and safety—especially for pediatric oral medications.
CurifyLabs isn’t stopping there. With the support of a €5.6 million EU-backed initiative, the company is also leading RoboPharma—a decentralized, AI-powered drug production platform aimed at improving crisis resilience in European healthcare. This project brings together six partners from across Finland, Sweden, France, Estonia, and Germany. The goal: enable hospitals and pharmacies to produce precision medicines on demand, right at the point of care.
As medicine moves toward personalized, just-in-time delivery, CurifyLabs is at the forefront of a €15 billion global compounding market growing at 5.5% annually. Its Pharma Printer is already in use at leading institutions like Germany’s Helios Klinikum Erfurt, where it’s improving safety and efficiency in daily workflows.
Unlike startups focused solely on remote diagnostics or record digitization, CurifyLabs addresses the last mile: how to deliver the right drug, in the right dose, in the right form—where and when it’s needed most.
CEO Charlotta Topelius summed it up: “Even the best-trained pharmacists are stuck using inefficient, manual methods. That means sick children, elderly patients, and others may not get what they need. Our mission is simple—bring automation and intelligence to pharmacy compounding so that every patient can receive medicine that’s made just for them.”
With regulatory alignment (including GMP-grade ink development and FDA/EMA compliance), CurifyLabs is poised to bring its solution to more pharmacies, hospitals, and ultimately patients across the globe.
